

Acerus Pharmaceuticals Corp (ASP) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/A42994DC120EN.html

Date: December 2021

Pages: 53

Price: US\$ 125.00 (Single User License)

ID: A42994DC120EN

Abstracts

Acerus Pharmaceuticals Corp (ASP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation develops, manufactures, markets and distributes novel innovative branded products. It focuses in the therapeutic areas of women's health (female sexual dysfunction, harmone replacement therapy) and men's health (urology). The company's marketed products include Estrace, for menopausal symptoms and Natesto, a testosterone for male hypogonadism. Acerus pipeline products include Tefina, Avanafil, Elegant and Lidbree indicated for various health issues related to men and women. The company sells products through its salesforce in Canada and licensed distributors in the US and other countries. The company is headquartered in Mississauga, Ontario, Canada.

Acerus Pharmaceuticals Corp Key Recent Developments

Nov 09,2021: Acerus Reports Fiscal Third Quarter Financial Results

Aug 12,2021: Acerus reports acceptance of part 36 settlement offer in recipharm

litigation

Aug 10,2021: Acerus Reports Fiscal 2021 Second Quarter Financial Results

Jul 12,2021: Acerus provides update on litigation with Recipharm

Jun 14,2021: Acerus Announces Voting Results for the 2021 Annual Meeting



Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.



Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Acerus Pharmaceuticals Corp - Key Facts

Acerus Pharmaceuticals Corp - Key Employees

Acerus Pharmaceuticals Corp - Key Employee Biographies

Acerus Pharmaceuticals Corp - Major Products and Services

Acerus Pharmaceuticals Corp - History

Acerus Pharmaceuticals Corp - Company Statement

Acerus Pharmaceuticals Corp - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

Acerus Pharmaceuticals Corp - Business Description

R&D Overview

Acerus Pharmaceuticals Corp - Corporate Strategy

Acerus Pharmaceuticals Corp - SWOT Analysis

SWOT Analysis - Overview

Acerus Pharmaceuticals Corp - Strengths

Acerus Pharmaceuticals Corp - Weaknesses

Acerus Pharmaceuticals Corp - Opportunities

Acerus Pharmaceuticals Corp - Threats

Acerus Pharmaceuticals Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 - COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES



Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Acerus Pharmaceuticals Corp, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Nov 09, 2021: Acerus Reports Fiscal Third Quarter Financial Results

Aug 12, 2021: Acerus reports acceptance of part 36 settlement offer in recipharm litigation

Aug 10, 2021: Acerus Reports Fiscal 2021 Second Quarter Financial Results

Jul 12, 2021: Acerus provides update on litigation with Recipharm

Jun 14, 2021: Acerus Announces Voting Results for the 2021 Annual Meeting

Mar 11, 2021: Acerus Reports Fourth Quarter and Full Year 2020 Financial Results

Mar 04, 2021: Acerus to Report 2020 Financial Results and Host Investor Call

Nov 03, 2020: Acerus reports fiscal third quarter financial results

Sep 14, 2020: Acerus announces addition of US commercial leader

Aug 11, 2020: Acerus reports fiscal 2020 second quarter financial results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer



List Of Tables

LIST OF TABLES

Acerus Pharmaceuticals Corp, Key Facts

Acerus Pharmaceuticals Corp, Key Employees

Acerus Pharmaceuticals Corp, Key Employee Biographies

Acerus Pharmaceuticals Corp, Major Products and Services

Acerus Pharmaceuticals Corp, History

Acerus Pharmaceuticals Corp, Subsidiaries

Acerus Pharmaceuticals Corp, Key Competitors

Acerus Pharmaceuticals Corp, Ratios based on current share price

Acerus Pharmaceuticals Corp, Annual Ratios

Acerus Pharmaceuticals Corp, Annual Ratios (Cont...1)

Acerus Pharmaceuticals Corp, Annual Ratios (Cont...2)

Acerus Pharmaceuticals Corp, Interim Ratios

Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Acerus Pharmaceuticals Corp, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios



List Of Figures

LIST OF FIGURES

Acerus Pharmaceuticals Corp, Performance Chart (2016 - 2020)

Acerus Pharmaceuticals Corp, Ratio Charts

Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Acerus Pharmaceuticals Corp (ASP) - Financial and Strategic SWOT Analysis Review

Product link: https://marketpublishers.com/r/A42994DC120EN.html

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A42994DC120EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970